8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 15, 2023

VEECO INSTRUMENTS INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation) 0-16244
(Commission
File Number) 11-2989601
(IRS Employer
Identification No.)

Terminal Drive, Plainview, New York 11803

(Address of principal executive offices)

(516) 677-0200

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	VECO	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 15, 2023, Veeco Instruments Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022. In connection with the release and the related conference call, Veeco posted a presentation relating to its fourth quarter and FY 2022 financial results on its website (www.veeco.com). Copies of the press release and presentation are furnished as Exhibit 99.1 and Exhibit 99.2 to this report.

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits.

EXHIBIT INDEX

Exhibit	Description
99.1	Press release issued by Veeco dated February 15, 2023
99.2	Veeco Q4 & FY 2022 Conference Call Presentation February 15, 2023
104	Cover Page Interactive Data File (formatted as inline XBRL).

Limitation on Incorporation by Reference

In accordance with general instruction B.2 of Form 8-K, the information in this report, including exhibits, is furnished pursuant to Items 2.02 and 9.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall this information or exhibits be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 15, 2023	VEECO INSTRUMENTS INC.
	By:	/s/ Kirk Mackey
	Name: Kirk Mackey
	Title: Vice President, General Counsel

2

EX-99.1

EXHIBIT 99.1

VEECO REPORTS FOURTH QUARTER AND FISCAL YEAR 2022 FINANCIAL RESULTS

Fourth Quarter 2022 Highlights:

● Revenues of $153.8 million, compared with $153.0 million in the same period last year

● GAAP net income of $128.9 million, or $2.00 per diluted share, compared with $8.2 million, or $0.15 per diluted share in the same period last year

● Non-GAAP net income of $21.9 million, or $0.38 per diluted share, compared with $22.6 million, or $0.43 per diluted share in the same period last year

Fiscal Year 2022 Highlights:

● Revenues of $646.1 million, compared with $583.3 million in the same period last year

● GAAP net income of $166.9 million, or $2.71 per diluted share, compared with $26.0 million, or $0.49 per diluted share in the same period last year

● Non-GAAP net income of $89.6 million, or $1.57 per diluted share, compared with $73.6 million, or $1.43 per diluted share in the same period last year

Plainview, N.Y., February 15, 2023 -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its fourth quarter and fiscal year ended December 31, 2022. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.  

U.S. Dollars in millions, except per share data

	4th Quarter				Full Year
GAAP Results	Q4 '22		Q4 '21		2022		2021
Revenue	$	153.8	$	153.0	$	646.1	$	583.3
Net income	$	128.9	$	8.2	$	166.9	$	26.0
Diluted earnings per share	$	2.00	$	0.15	$	2.71	$	0.49

	4th Quarter				Full Year
Non-GAAP Results	Q4 '22		Q4 '21		2022		2021
Operating income	$	23.8	$	24.9	$	99.8	$	86.6
Net income	$	21.9	$	22.6	$	89.6	$	73.6
Diluted earnings per share	$	0.38	$	0.43	$	1.57	$	1.43

“2022 was another year of growth for Veeco,” commented Bill Miller, Ph.D., Veeco’s Chief Executive Officer. “We achieved record revenue with our semiconductor products led by increased traction in laser annealing for both advanced and trailing nodes. We grew our backlog with strong order activity while also strengthening our balance sheet with robust cashflow from operations.”

“We enter 2023 cautiously optimistic,” continued Dr. Mr. Miller. “We’re focused on investing R&D in our product roadmaps and integrating our recently acquired silicon carbide epitaxy business. We expect to outperform the wafer fab equipment market with our semiconductor products, grow in the data storage market and maintain profitability during the current macroeconomic challenges.”

1

Guidance and Outlook

The following guidance is provided for Veeco’s first quarter 2023:

● Revenue is expected in the range of $130 million to $150 million

● GAAP diluted earnings (loss) per share are expected in the range of $(0.03) to $0.16

● Non-GAAP diluted earnings per share are expected in the range of $0.12 to $0.28

Conference Call Information

A conference call reviewing these results has been scheduled for today, February 15, 2023 starting at 5:00pm ET. To join the call, dial 1-877-407-8029 (toll free) or 1-201-689-8029. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.

About Veeco

Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

Forward-looking Statements

This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, the impact of the COVID-19 pandemic, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; the effects of regional or global health epidemics, including the effects of the COVID-19 pandemic on the Company’s operations and on those of our customers and suppliers;  global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this press release or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

-financial tables attached-

Veeco Contacts:

Investors:Anthony Bencivenga (516) 252-1438abencivenga@veeco.com

Media:Kevin Long (516) 714-3978klong@veeco.com

2

Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)
(unaudited)

	Three months ended December 31,				Year ended December 31,
	2022		2021		2022		2021
Net sales	$	153,799	$	152,972	$	646,137	$	583,277
Cost of sales		90,881		88,949		382,989		341,003
Gross profit		62,918		64,023		263,148		242,274
Operating expenses, net:
Research and development		26,327		22,283		103,565		88,680
Selling, general, and administrative		20,965		21,211		88,952		84,536
Amortization of intangible assets		2,505		2,974		10,018		12,280
Other operating expense (income), net		(271)		(71)		317		68
Total operating expenses, net		49,526		46,397		202,852		185,564
Operating income		13,392		17,626		60,296		56,710
Interest expense, net		(1,558)		(5,799)		(9,311)		(26,020)
Other income (expense), net		—		(5,010)		—		(5,010)
Income before income taxes		11,834		6,817		50,985		25,680
Income tax expense (benefit)		(117,081)		(1,387)		(115,957)		(358)
Net income	$	128,915	$	8,204	$	166,942	$	26,038
Income per common share:
Basic	$	2.58	$	0.17	$	3.35	$	0.53
Diluted	$	2.00	$	0.15	$	2.71	$	0.49
Weighted average number of shares:
Basic		49,912		49,187		49,906		49,073
Diluted		65,684		54,931		65,607		53,643

3

Veeco Instruments Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in thousands)

	December 31,		December 31,
	2022		2021
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	154,925	$	119,747
Restricted cash		547		725
Short-term investments		147,488		104,181
Accounts receivable, net		124,221		109,609
Contract assets		16,507		18,293
Inventories		206,908		170,858
Prepaid expenses and other current assets		18,305		25,974
Total current assets		668,901		549,387
Property, plant and equipment, net		107,281		99,743
Operating lease right-of-use assets		26,467		28,813
Intangible assets, net		23,887		33,905
Goodwill		181,943		181,943
Deferred income taxes		116,349		1,639
Other assets		3,355		3,546
Total assets	$	1,128,183	$	898,976
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	52,049	$	44,456
Accrued expenses and other current liabilities		56,031		79,752
Customer deposits and deferred revenue		127,223		63,136
Income taxes payable		2,432		1,860
Current portion of long-term debt		20,169		—
Total current liabilities		257,904		189,204
Deferred income taxes		1,285		4,792
Long-term debt		254,491		229,438
Long-term operating lease liabilities		33,581		32,834
Other liabilities		3,098		5,080
Total liabilities		550,359		461,348
Total stockholders’ equity		577,824		437,628
Total liabilities and stockholders’ equity	$	1,128,183	$	898,976

Note on Reconciliation Tables

The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.

These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors’ operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.

4

Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2022)

(in thousands)
(unaudited)

				Non-GAAP Adjustments
				Share-Based
Three months ended December 31, 2022	GAAP			Compensation	Amortization	Other		Non-GAAP
Net sales	$	153,799						$	153,799
Gross profit		62,918		1,167		1,011			65,096
Gross margin		40.9	%						42.3	%
Operating expenses		49,526		(4,858)	(2,505)	(821)			41,342
Operating income		13,392		6,025	2,505	1,832	^		23,754
Net income		128,915		6,025	2,505	(115,554)	^		21,891

^ - See table below for additional details.

Other Non-GAAP Adjustments (Q4 2022)

(in thousands)
(unaudited)

Three months ended December 31, 2022
Transition expenses related to San Jose expansion project	$	1,788
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		44
Subtotal		1,832
Non-cash interest expense		244
Release of valuation allowance on deferred tax assets		(104,971)
Non-GAAP tax adjustment *		(12,659)
Total Other	$	(115,554)

* - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Net Income per Common Share (Q4 2022)

(in thousands, except per share amounts)
(unaudited)

	Three months ended December 31, 2022
	GAAP		Non-GAAP
Numerator:
Net income	$	128,915	$	21,891
Interest expense associated with convertible notes		2,712		2,467
Net income available to common shareholders	$	131,627	$	24,358
Denominator:
Basic weighted average shares outstanding		49,912		49,912
Effect of potentially dilutive share-based awards		805		805
Dilutive effect of 2023 Convertible Senior Notes		504		504
Dilutive effect of 2025 Convertible Senior Notes		5,521		5,521
Dilutive effect of 2027 Convertible Senior Notes (1)		8,942		6,771
Diluted weighted average shares outstanding		65,684		63,513
Net income per common share:
Basic	$	2.58	$	0.44
Diluted	$	2.00	$	0.38

⁽¹⁾    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

5

Reconciliation of GAAP to Non-GAAP Financial Data (Q4 2021)

(in thousands, except per share amounts)
(unaudited)

				Non-GAAP Adjustments
				Share-based
Three months ended December 31, 2021		GAAP		Compensation	Amortization	Other		Non-GAAP
Net sales	$	152,972						$	152,972
Gross profit		64,023		608		235			64,866
Gross margin		41.9	%						42.4	%
Operating expenses		46,397		(2,906)	(2,974)	(537)			39,980
Operating income		17,626		3,514	2,974	772	^		24,886
Net income		8,204		3,514	2,974	7,950	^		22,642
Income per common share:
Basic	$	0.17						$	0.46
Diluted		0.15							0.43
Weighted average number of shares:
Basic		49,187							49,187
Diluted (1)		54,931							52,761

^ - See table below for additional details.

⁽¹⁾    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, no incremental shares are added to the dilutive share count in periods in which the average stock price per share is below $18.46. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, incremental shares are added to the dilutive share count in periods in which the average stock price per share is above $13.98, and the Company is in a net income position. The average stock price for the three months ended December 31, 2021 was $25.53, and therefore 1.9 million shares were included in the non-GAAP diluted share count, and 4.0 million shares were included in the GAAP diluted share count related to the 2027 Notes.

Other Non-GAAP Adjustments (Q4 2021)

(in thousands)
(unaudited)

Three months ended December 31, 2021
Transition expenses related to San Jose expansion project	$	698
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		74
Subtotal		772
Non-cash interest expense		3,057
Other (income) expense, net		5,010
Non-GAAP tax adjustment *		(889)
Total Other	$	7,950

* - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

6

Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q4 2022 and 2021)

(in thousands)
(unaudited)

	Three months ended		Three months ended
	December 31, 2022		December 31, 2021
GAAP Net income	$	128,915	$	8,204
Share-based compensation		6,025		3,514
Amortization		2,505		2,974
Transition expenses related to San Jose expansion project		1,788		698
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		44		74
Interest (income) expense, net		1,558		5,799
Other (income) expense, net		—		5,010
Income tax expense (benefit)		(117,081)		(1,387)
Non-GAAP Operating income	$	23,754	$	24,886

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2022)

(in thousands)
(unaudited)

				Non-GAAP Adjustments
				Share-based
For the year ended December 31, 2022		GAAP		Compensation	Amortization	Other		Non-GAAP
Net sales	$	646,137						$	646,137
Gross profit		263,148		4,551		3,300			270,999
Gross margin		40.7	%						41.9	%
Operating expenses		202,852		(18,443)	(10,018)	(3,212)			171,179
Operating income (loss)		60,296		22,994	10,018	6,512	^		99,820
Net income (loss)		166,942		22,994	10,018	(110,379)	^		89,575

^ - See table below for additional details.

Other Non-GAAP Adjustments (FY 2022)

(in thousands)
(unaudited)

For the year ended December 31, 2022
Transition expenses related to San Jose expansion project	$	6,202
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		310
Subtotal		6,512
Non-cash interest expense		962
Release of valuation allowance on deferred tax assets		(104,971)
Non-GAAP tax adjustment *		(12,882)
Total Other	$	(110,379)

* - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

7

Net Income per Common Share (FY 2022)

(in thousands, except per share amounts)
(unaudited)

	Year ended December 31, 2022
	GAAP		Non-GAAP
Numerator:
Net income	$	166,942	$	89,575
Interest expense associated with convertible notes		10,832		9,870
Net income available to common shareholders	$	177,774	$	99,445
Denominator:
Basic weighted average shares outstanding		49,906		49,906
Effect of potentially dilutive share-based awards		734		734
Dilutive effect of 2023 Convertible Senior Notes		504		504
Dilutive effect of 2025 Convertible Senior Notes		5,521		5,521
Dilutive effect of 2027 Convertible Senior Notes (1)		8,942		6,771
Diluted weighted average shares outstanding		65,607		63,436
Net income per common share:
Basic	$	3.35	$	1.79
Diluted	$	2.71	$	1.57

⁽¹⁾    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP to Non-GAAP Financial Data (FY 2021)

(in thousands, except per share amounts)
(unaudited)

				Non-GAAP Adjustments
				Share-based
For the year ended December 31, 2021		GAAP		Compensation	Amortization	Other		Non-GAAP
Net sales	$	583,277						$	583,277
Gross profit		242,274		2,373		448			245,095
Gross margin		41.5	%						42.0	%
Operating expenses		185,564		(12,876)	(12,280)	(1,918)			158,490
Operating income (loss)		56,710		15,249	12,280	2,366	^		86,605
Net income (loss)		26,038		15,249	12,280	20,082	^		73,649
Income (loss) per common share:
Basic	$	0.53						$	1.50
Diluted		0.49							1.43
Weighted average number of shares:
Basic		49,073							49,073
Diluted		53,643							51,472

^ - See table below for additional details.

8

Other Non-GAAP Adjustments (FY 2021)

(in thousands)
(unaudited)

For the year ended December 31, 2021
Transition expenses related to San Jose expansion project	$	2,021
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		345
Subtotal		2,366
Non-cash interest expense		13,819
Other (income) expense, net		5,010
Non-GAAP tax adjustment *		(1,113)
Total Other	$	20,082

* - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.

Reconciliation of GAAP Net Income to Non-GAAP Operating Income (FY 2022 and 2021)

(in thousands)
(unaudited)

	Year ended		Year ended
	December 31, 2022		December 31, 2021
GAAP Net income (loss)	$	166,942	$	26,038
Share-based compensation		22,994		15,249
Amortization		10,018		12,280
Transition expenses related to San Jose expansion project		6,202		2,021
Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting		310		345
Interest (income) expense, net		9,311		26,020
Other (income) expense, net		—		5,010
Income tax expense (benefit)		(115,957)		(358)
Non-GAAP Operating income (loss)	$	99,820	$	86,605

Reconciliation of GAAP to Non-GAAP Financial Data (Q1 2023)

(in millions, except per share amounts)

(unaudited)

						Non-GAAP Adjustments
Guidance for the three months ending						Share-based
March 31, 2023	GAAP					Compensation	Amortization	Other	Non-GAAP
Net sales	$	130	-	$	150				$	130	-	$	150
Gross profit		48	-		61	1	—	—		49	-		62
Gross margin		37%	-		40%					39%	-		41%
Operating expenses		49	-		51	(5)	(2)	(1)		42	-		44
Operating income (loss)		(1)	-		10	6	2	1		8	-		19
Net income (loss)	$	(1)	-	$	8	6	2	(1)	$	6	-	$	15
Income (loss) per diluted common share	$	(0.03)	-	$	0.16				$	0.12	-	$	0.28

9

Income per Diluted Common Share (Q1 2023)

(in millions, except per share amounts)
(unaudited)

Guidance for the three months ending March 31, 2023	GAAP					Non-GAAP
Numerator:
Net income (loss)	$	(1)	-	$	8	$	6	-	$	15
Interest expense associated with convertible notes		—			1		—			2
Net income (loss) available to common shareholders	$	(1)	-	$	9	$	6	-	$	17
Denominator:
Basic weighted average shares outstanding		50			50		50			50
Effect of potentially dilutive share-based awards		1			1		1			1
Dilutive effect of 2023 Convertible Senior Notes		—			—		—			—
Dilutive effect of 2025 Convertible Senior Notes		—			—		—			6
Dilutive effect of 2027 Convertible Senior Notes (1)		—			9		—			7
Diluted weighted average shares outstanding		51			60		51			64
Net income (loss) per common share:
Income (loss) per diluted common share	$	(0.03)	-	$	0.16	$	0.12	-	$	0.28

⁽¹⁾    - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.

Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q1 2023)

(in millions)
(unaudited)

Guidance for the three months ending March 31, 2023
GAAP Net income (loss)	$	(1)	-	$	8
Share-based compensation		6	-		6
Amortization		2	-		2
Interest expense, net		1	-		1
Income tax expense (benefit)		—	-		1
Other		—	-		1
Non-GAAP Operating income	$	8	-	$	19

Note: Amounts may not calculate precisely due to rounding.

10

EX-99.2

Exhibit 99.2

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 1 Veeco (Nasdaq: VECO) February 15, 2023 Q4 & FY 2022 Financial Results Conference Call

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 2 Safe Harbor This presentation contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, the impact of the COVID-19 pandemic, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; the effects of regional or global health epidemics, including the effects of the COVID-19 pandemic on the Company’s operations and on those of our customers and suppliers; global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this presentation. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 3 CEO Overview Bill Miller, Ph.D.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 4 2022 – A Year of Progress Solidly Executing Multi-Year Growth Strategy ✓ Progress in laser annealing, IBD for semi, power, photonics ✓ Robust evaluation program in place with high customer acceptance rate ✓ San Jose expansion – Completed Achieved Leveraged Growth ✓ 11% overall revenue growth for Company ✓ Non-GAAP operating income grew faster than revenue Developed Silicon Carbide Market Strategy ✓ Accelerate SiC market penetration via acquisition ✓ Long-term driver of growth and profitability Commitment to Culture and Corporate Responsibility ✓ Appointed additional female Board member ✓ Published 3rd sustainability report highlighting commitment to ESG ✓ Implemented Leadership Training Program Positioned for solid 2023 ✓ Positive book-to-bill with significant backlog growth ✓ Strengthened balance sheet with robust cash flow from operations IBD – Ion Beam Deposition SiC – Silicon Carbide ESG – Environmental, Social, Governance A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 5 FY 2022 Highlights $646M $100M $1.57 Revenue Non-GAAP Operating Income Diluted Non-GAAP EPS • 11% YoY revenue growth • Record year of semiconductor revenue • Up 50% YoY • Led by Laser Annealing • Backlog grew by $60M to $500M • $108M in CFFO • Mixed demand environment • Supply chain challenges persist Solid performance in a challenging environment A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 6 Q4 2022 Highlights $154M $24M 38¢ Revenue Non-GAAP Operating Income Diluted Non-GAAP EPS • Semiconductor momentum continues • $33M in CFFO • Mixed demand environment • Supply chain challenges persist with signs of improvement Solid quarter in a challenging environment A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 7 Veeco Acquires Epiluvac – Deal Rationale • Veeco to enter SiC market faster • Epiluvac’s team along with Veeco’s capability will fast-track product roadmap execution • Epiluvac’s system achieves high productivity, is easy to maintain and has superior process control • Veeco’s supply chain, manufacturing and go-to-market capabilities will facilitate product ramp and accelerate market penetration 2 3 1 • Veeco expects meaningful value creation resulting from expansion into the SiC epitaxy equipment market Accelerated Access to High-Growth SiC Markets Complementary Technology and Capabilities Long-Term Driver of Growth and Profitability

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 8 Epiluvac Extends Veeco’s Reach into SiC Epitaxy Market ▪ Rapidly growing demand for SiC devices driven by multiple strong and stable end-markets including automotive, industrial and energy ▪ SiC device market is expected to experience significant growth translating into strong demand for SiC epitaxy equipment ▪ Large future revenue opportunity attracting significant investment from many key players in the semiconductor industry (1) Worldwide SiC device total available market estimates according to Yole Group (2) SiC epitaxy equipment total available market estimates according to Yole Group and internal estimates 2023 2027 2023 2027 ~15% CAGR ~30% CAGR SiC Epitaxy Equip. Market (2) SiC Device Market (1) ~$2B ~$6B ~$250M ~$500M

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 9 Veeco Acquires Epiluvac – Transaction Overview ▪ Veeco acquired Epiluvac AB, a privately held Swedish manufacturer of Silicon Carbide (SiC) epitaxy systems ▪ Purchase price is $30 million of cash upfront from Veeco’s balance sheet ▪ Additional performance based earn-outs up to $35 million ▪ Transaction closed on January 31, 2023 ▪ Epiluvac is an early-stage revenue company with 11 employees ▪ Impact to Veeco’s Non-GAAP financial results is not expected to be material in 2023 ▪ Revenue expected in 2024 ▪ Deal is expected to be slightly accretive to Non-GAAP EPS in 2024

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 10 CFO Financial Review John Kiernan

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 11 FY 2022 Revenue by Market & Region 57% 19% 13% 11% Revenue by Market Revenue by Region Scientific & Other Semiconductor Compound Semiconductor Data Storage 36% 31% 19% 14% EMEA China United States Rest of APAC $646M Revenue Trend ($M) FY 20 FY 21 FY 22 Semiconductor 166 247 369 Compound Semi 108 107 121 Data Storage 123 169 88 Scientific & Other 57 60 68 Total 454 583 646 Amounts may not calculate precisely due to rounding. ROW is negligible

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 12 FY Operating Results In millions (except per share amounts) GAAP Non-GAAP FY 21 FY 22 FY 21 FY 22 Revenue $583.3 $646.1 $583.3 $646.1 Gross Profit 242.3 263.1 245.1 271.0 Gross Margin 41.5% 40.7% 42.0% 41.9% Operating Expenses 185.6 202.9 158.5 171.2 Operating Income 56.7 60.3 86.6 99.8 Net Income 26.0 166.9 73.6 89.6 Diluted Earnings Per Share $0.49 $2.71 $1.43 $1.57 Diluted Shares 53.6 65.6 51.5 63.4 Amounts may not calculate precisely due to rounding. A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 13 Q4 2022 Revenue by Market & Region 16% 61% 11% 12% Revenue by Market Revenue by Region Scientific & Other Semiconductor Compound Semiconductor Data Storage 42% 25% 19% 14% EMEA China United States Rest of APAC $154M Revenue Trend ($M) Q4 21 Q3 22 Q4 22 Semiconductor 65 100 94 Compound Semi 35 28 25 Data Storage 37 28 17 Scientific & Other 16 16 18 Total 154 172 154 Amounts may not calculate precisely due to rounding. ROW is negligible

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 14 Q4 Operating Results In millions (except per share amounts) GAAP Non-GAAP Q3 22 Q4 22 Q3 22 Q4 22 Revenue $171.9 $153.8 $171.9 $153.8 Gross Profit 70.0 62.9 72.2 65.1 Gross Margin 40.7% 40.9% 42.0% 42.3% Operating Expenses 52.4 49.5 43.9 41.3 Operating Income 17.6 13.4 28.4 23.8 Net Income 15.0 128.9 26.0 21.9 Diluted Earnings Per Share $0.27 $2.00 $0.45 $0.38 Diluted Shares 65.2 65.7 63.5 63.5 Amounts may not calculate precisely due to rounding. A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 15 Balance Sheet and Cash Flow Highlights $ millions Q4 21 Q3 22 Q4 22 Cash & Short-Term Investments 225 272 303 Accounts Receivable 110 143 124 Inventories 171 188 207 Accounts Payable 44 51 52 Long-Term Debt Including Current Portion 229 274 275 Cash Flow from Operations 17 47 33 DSO (days) 64 75 73 DIO 173 161 196 DPO 46 46 52 Capital Expenditures 9 6 3 Amounts may not calculate precisely due to rounding. A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 16 Q1 2023 Guidance GAAP Non-GAAP Revenue $130M - $150M $130M - $150M Gross Margin 37% - 40% 39% - 41% Operating Expenses $49M - $51M $42M - $44M Net Income / (Loss) $(1M) - $8M $6M - $15M Diluted Earnings / (Loss) Per Share $(0.03) – $0.16 $0.12 - $0.28 A reconciliation of GAAP to Non-GAAP financial measures can be found in the backup section of this presentation.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 17 Market Update Bill Miller, Ph.D.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 18 Mobility and Immersive User Experience Connecting people on the move with technologies such as 5G, sensors, advanced displays The Cloud High speed communication and storage of enormous amounts of data Differentiated Technologies Aligned with Megatrends Compound Semiconductor Semiconductor Megatrends Growth Markets Core Technologies Laser Annealing AP Lithography Ion Beam Wet Processing MOCVD Transformation of the Automotive Industry Electrification and autonomous advancements High Performance Computing/AI Faster and more efficient computing to enable large scale data center applications and artificial intelligence Data Storage Ion Beam Deposition Ion Beam Etch AI – Artificial Intelligence 5G – Fifth generation wireless technology CVD – Chemical Vapor Deposition AP – Advanced Packaging MOCVD – Metal Organic Chemical Vapor Deposition SiC CVD

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 19 2023 Priorities – Executing Our Growth Strategy Protect ▪ Product Development ▪ Advance evaluation program ▪ SiC market penetration ▪ Safety ▪ Culture ▪ Outperform WFE in Semiconductor revenue ▪ Revenue growth in Data Storage ▪ Maintain profitability ▪ Supply chain ▪ Customer satisfaction Growth & Profitability Committed to our strategy through a challenging macro environment Execute Innovate & Invest Strategy Execution

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 20 Thank You Q&A

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 21 Backup and Financial Tables

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 22 Historical Revenue by End-Market $M 2019 2020 2021 2022 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Semiconductor 175.6 37.4 37.5 33.6 57.4 165.9 51.6 53.7 76.3 65.4 247.1 77.6 97.5 100.4 93.8 369.4 Compound Semi 85.9 18.4 17.8 26.6 45.2 107.9 24.8 24.2 23.3 34.7 107.0 37.1 31.1 28.1 24.9 121.2 Data Storage 84.1 38.9 28.3 36.9 19.2 123.3 41.0 52.0 39.3 36.5 168.8 21.6 21.5 27.7 16.7 87.5 Scientific & Other 73.8 9.8 15.1 15.0 17.1 57.0 16.4 16.4 11.4 16.3 60.5 20.1 13.8 15.7 18.4 68.0 Total 419.3 104.5 98.6 112.1 138.9 454.2 133.7 146.3 150.2 153.0 583.3 156.4 164.0 171.9 153.8 646.1 Amounts may not calculate precisely due to rounding.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 23 Convertible Notes as of December 31, 2022 (1) Conversion price for 2027 Convertible Notes includes the effect of the Capped Call transaction (2) Weighted average (3) Reflects the adoption of ASU 2020-06, effective January 1, 2022 (4) In January 2023, our $20.2 million dollars of outstanding 2.70% convertible senior notes matured and were fully settled by payment in cash. Amounts may not calculate precisely due to rounding. Convertible Debt Principal Amount Carrying Value Coupon Annual Cash Interest Annual Non-Cash Interest3 Initial Conversion Price Convertible Notes Due Jan 2023 $20M $20M 2.7% $0.5M $0.1M $40.03 Convertible Notes Due Jan 2025 $133M $131M 3.5% $4.6M $0.5M $24.00 Convertible Notes Due June 2027 $125M $123M 3.75% $4.7M $0.4M $18.461 Total Convertible Debt $278M $274M 3.6%2 $9.8M $0.9M Total Convertible Debt as of January 15, 20234 $258M $254M 3.6%2 $9.3M $0.9M

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 24 Note on Reconciliation Tables These tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, incremental transaction-related compensation, and certain integration costs. These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors' operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating Income, which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 25 Supplemental Information—GAAP to Non-GAAP Reconciliation Amounts may not calculate precisely due to rounding. In millions Q3 22 Q4 22 2022 2021 Net sales $171.9 $153.8 $646.1 583.3 GAAP gross profit 70.0 62.9 263.1 242.3 GAAP gross margin 40.7% 40.9% 40.7% 41.5% Add: Share-based comp 1.2 1.2 4.6 2.4 Add: Other 1.1 1.0 3.3 0.4 Non-GAAP gross profit $72.2 $65.1 $271.0 $245.1 Non-GAAP gross margin 42.0% 42.3% 41.9% 42.0% In millions Q3 22 Q4 22 2022 2021 GAAP Net income $15.0 $128.9 $166.9 $26.0 Add: Share-based comp 6.2 6.0 23.0 15.2 Add: Amortization 2.5 2.5 10.0 12.3 Add: Transition expenses related to San Jose expansion project 1.9 1.8 6.2 2.0 Add: Depreciation of PP&E fair value step-up for purchase accounting 0.1 - 0.3 0.3 Add: Interest expense 2.3 1.6 9.3 26.0 Add: Other (income) expense, net 0.2 - - 5.0 Add: Tax expense (benefit) 0.2 (117.1) (116.0) (0.4) Non-GAAP operating income $28.4 $23.8 $99.8 $86.6 In millions, except per share amounts Q3 22 Q4 22 2022 2021 GAAP Basic weighted average shares 49.9 49.9 49.9 49.1 GAAP Diluted weighted average shares 65.2 65.7 65.6 53.6 GAAP Basic EPS $0.30 $2.58 $3.35 $0.53 GAAP Diluted EPS $0.27 $2.00 $2.71 $0.49 GAAP Net income $15.0 $128.9 $166.9 $26.0 Add: Share-based comp 6.2 6.0 23.0 15.2 Add: Amortization 2.5 2.5 10.0 12.3 Add: Transition expenses related to San Jose expansion project 1.9 1.8 6.2 2.0 Add: Depreciation of PP&E fair value step-up for purchase accounting 0.1 - 0.3 0.3 Add: Non-cash interest expense 0.2 0.2 0.9 13.8 Add: Other (income) expense, net - - - 5.0 Add: Release of valuation allowance on DTA - (105.0) (105.0) - Add: Tax adjustment from GAAP to Non-GAAP (0.1) (12.7) (12.9) (1.1) Non-GAAP net income $26.0 21.9 89.6 $73.6 Non-GAAP basic EPS $0.52 $0.44 $1.79 $1.50 Non-GAAP diluted EPS $0.45 $0.38 $1.57 $1.43 Non-GAAP basic weighted average shares 49.9 49.9 49.9 49.1 Non-GAAP diluted weighted average shares 63.5 63.5 63.4 51.5 In millions Q3 22 Q4 22 2022 2021 GAAP operating expenses 51.4 $49.5 $202.9 $185.6 Share-based compensation (5.0) (4.9) (18.4) (12.9) Amortization (2.5) (2.5) (10.0) (12.3) Other (1.0) (0.8) (3.2) (1.9) Non-GAAP operating expenses 43.9 $41.3 $171.2 $158.5

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 26 Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $153.8 $153.8 Gross Profit 62.9 1.2 — 1.0 65.1 Gross Margin 40.9% 42.3% Operating Expenses $49.5 (4.9) (2.5) (0.8) $41.3 Operating Income $13.4 6.0 2.5 1.8 $23.8 Net Income $128.9 6.0 2.5 (115.6) $21.9 Q4 2022 Actual: GAAP to Non-GAAP Reconciliation Amounts may not calculate precisely due to rounding. Income per Diluted Common Share GAAP Non-GAAP Net Income $128.9 $21.9 Add: Interest on Convertible Senior Notes 2.7 2.5 Net income available to common shareholders 131.6 24.4 Basic weighted average common shares 49.9 49.9 Add: Dilutive effect of share-based awards 0.8 0.8 Add: Dilutive effect of 2023 Convertible Senior Notes 0.5 0.5 Add: Dilutive effect of 2025 Convertible Senior Notes 5.5 5.5 Add: Dilutive effect of 2027 Convertible Senior Notes 8.9 6.8 Diluted weighted average common shares 65.7 63.5 Basic income per common share $2.58 $0.44 Diluted income per common share $2.00 $0.38 Other Non-GAAP Adjustments Transition expenses related to San Jose expansion project $1.8 Subtotal 1.8 Non-cash Interest Expense 0.2 Release of valuation allowance on deferred tax assets (105.0) Non-GAAP tax adjustment (12.7) Total Other $(115.6)

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 27 FY 2022 Actual: GAAP to Non-GAAP Reconciliation Amounts may not calculate precisely due to rounding. Income per Diluted Common Share GAAP Non-GAAP Net Income $166.9 $89.6 Add: Interest on Convertible Senior Notes 10.8 9.8 Net income available to common shareholders 177.8 99.4 Basic weighted average common shares 49.9 49.9 Add: Dilutive effect of share-based awards 0.7 0.7 Add: Dilutive effect of 2023 Convertible Senior Notes 0.5 0.5 Add: Dilutive effect of 2025 Convertible Senior Notes 5.5 5.5 Add: Dilutive effect of 2027 Convertible Senior Notes 8.9 6.8 Diluted weighted average common shares 65.6 63.4 Basic income per common share $3.35 $1.79 Diluted income per common share $2.71 $1.57 Other Non-GAAP Adjustments Transition expenses related to San Jose expansion project $6.2 Depreciation of PPE fair value step-up associated with the Ultratech purchase accounting 0.3 Subtotal 6.5 Non-cash Interest Expense 0..9 Release of valuation allowance on deferred tax assets (105.0) Non-GAAP tax adjustment (12.9) Total Other $110.4 Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $646.1 $646.1 Gross Profit 263.1 4.6 — 3.3 271.0 Gross Margin 40.7% 41.9% Operating Expenses $202.9 (18.4) (10.0) (3.2) $171.2 Operating Income $60.3 23.0 10.0 6.5 $99.8 Net Income $166.9 23.0 10.0 (110.4) $89.6

Q4 & FY 2022 Financial Results Conference Call Copyright © 2023 Veeco Instruments Inc. All Rights Reserved. 28 Reconciliation of GAAP to non-GAAP Financial Data Non-GAAP Adjustments GAAP Share-Based Compensation Amortization Other Non-GAAP Net Sales $130–$150 $130–$150 Gross Profit 48–61 1 — — 49–62 Gross Margin 37%–40% 39%–41% Operating Expenses $49–$51 (5) (2) (1) $42–$44 Operating Income $(1)–$10 6 2 1 $8–$19 Net Income $(1)–$8 6 2 (1) $6–$15 Income per Diluted Share $(0.03)–$0.16 $0.12–$0.28 Q1 2023 Guidance (in millions, except per share amounts) Amounts may not calculate precisely due to rounding. Income per Diluted Common Share GAAP Non-GAAP Net Income $(1)–$8 $6–$15 Add: Interest on Convertible Senior Notes 0-1 0-2 Net income available to common shareholders (1)-9 6-17 Basic weighted average common shares 50 50 Add: Dilutive effect of share-based awards 1 1 Add: Dilutive effect of 2023 Convertible Senior Notes - - Add: Dilutive effect of 2025 Convertible Senior Notes - 0-6 Add: Dilutive effect of 2027 Convertible Senior Notes 0-9 0-7 Diluted weighted average common shares 51-60 51-64 Income per diluted common share $(0.03)-$0.16 $0.12-$0.28 Reconciliation of GAAP Net Income to non-GAAP Operating Income GAAP Net Income $(1)–$8 Share-Based Compensation 6 Amortization 2 Interest Expense, Net 1 Income tax expense (benefit) 0-1 Other 0–1 Non-GAAP Operating Income $8–$19

XML

Document and Entity Information	Feb. 15, 2023
Cover [Abstract]
Document Type	8-K
Document Period End Date	Feb. 15, 2023
Entity Registrant Name	VEECO INSTRUMENTS INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	0-16244
Entity Tax Identification Number	11-2989601
Entity Address, Address Line One	Terminal Drive
Entity Address, City or Town	Plainview
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11803
City Area Code	516
Local Phone Number	677-0200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	VECO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0000103145
Amendment Flag	false